AllRock Bio is a technology company.
AllRock Bio has raised $50.0M across 1 funding round.
AllRock Bio has raised $50.0M in total across 1 funding round.
AllRock Bio is a clinical-stage biotechnology company developing novel therapies for cardiopulmonary and fibrotic diseases, primarily targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD).[1][2][3][4] Its lead product, ROC-101, is an oral, first-in-class pan-ROCK inhibitor licensed from Sanofi, designed to address inflammatory, proliferative, and fibrotic pathways in these life-threatening conditions with limited treatment options.[2][4][5] The company serves patients with PAH (five-year survival ~57%) and ILD-PH (~38%), solving unmet needs beyond symptom relief by targeting disease drivers like vascular remodeling.[4][5] Launched in 2024 with a $50 million Series A co-led by Versant Ventures and Westlake BioPartners, AllRock shows strong early momentum, planning Phase 2a trials (ROCsTAR) in 2025 to test ROC-101 alongside standard therapies.[2][4][6]
AllRock Bio was founded in 2024 by a team of former CinCor Pharma executives, including co-founder and CEO Catherine Pearce, DHSc, MBA, who bring cardiovascular drug development expertise from CinCor's successful path to AstraZeneca's $1.3 billion acquisition in 2022 for its hypertension drug baxdrostat.[2][5][6] Chief Scientific Officer Bill Marshall and others identified ROC-101—originally from Kadmon (acquired by Sanofi in 2021)—after consulting key opinion leaders (KOLs) on the need for pan-ROCK inhibition targeting both ROCK1 and ROCK2.[2][4][5] The idea emerged from recognizing ROCK inhibitors' validation in glaucoma and their potential in PAH's fibrotic clogging of pulmonary arteries, leading to an exclusive license from Sanofi and a $50 million launch round backed by prior CinCor investors like David Allison of Westlake BioPartners.[2][4][6] Early traction includes Phase 1 safety data supporting Phase 2 advancement.[4]
AllRock rides the wave of precision therapies for rare cardiopulmonary diseases, where PAH and fibrotic lung conditions affect limited patients but demand innovation amid stagnant survival rates and few disease-modifying options.[4][5] Timing aligns with ROCK pathway validation—FDA-approved for glaucoma and in other pipelines—now expanding to lungs, fueled by big pharma licensing (e.g., Sanofi, AstraZeneca precedents).[2][5] Market forces favor it: biotech M&A appetite for validated assets, investor confidence from team history, and regulatory push for orphan drugs in high-mortality areas.[2][6] AllRock influences the ecosystem by accelerating pan-ROCK class development, potentially enabling combo regimens and inspiring fibrosis-focused biotechs.[1][4]
AllRock's near-term catalyst is the 2025 Phase 2a readout, which could validate ROC-101's transformative potential and draw partnerships or further funding, building on its $50 million war chest and pipeline expansion.[2][4][6] Rising focus on fibrosis modifiers and AI-driven trial design will shape its path, positioning it for Phase 3 or acquisition akin to CinCor. As a nimble player with battle-tested leadership, AllRock could redefine PAH treatment, delivering the efficient, patient-centric therapies it champions from day one.[1][3]
AllRock Bio has raised $50.0M in total across 1 funding round.
AllRock Bio's investors include Versant Ventures, Westlake Village BioPartners.
AllRock Bio has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $50.0M Series A | Versant Ventures, Westlake Village BioPartners |